Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Sherman

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
JCO Oncology Practice|December 19, 2025
Increasing Access and Quality Care for Immune Checkpoint Inhibitor-Related Thyroid DysfunctionAnne K Brinkman, Amori Y Salami-Henry, Lori A Aaron-Brija, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerMartin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
Head & Neck|February 14, 2019
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profilingSaad A Khan, Bo Ci, Yang Xie, et al.
Thyroid : Official Journal of the American Thyroid Association|October 29, 2009
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, David S Cooper, Gerard M Doherty, et al.
Thyroid : Official Journal of the American Thyroid Association|January 4, 2007
Outcomes of patients with differentiated thyroid carcinoma following initial therapyJacqueline Jonklaas, Nicholas J Sarlis, Danielle Litofsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawalHeribert Hänscheid, Michael Lassmann, Markus Luster, et al.
Thyroid : Official Journal of the American Thyroid Association|June 5, 2013
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosisDonald S A McLeod, David S Cooper, Paul W Ladenson, et al.
Thyroid : Official Journal of the American Thyroid Association|September 24, 2009
Recurrence after treatment of micropapillary thyroid cancerDouglas S Ross, Danielle Litofsky, Kenneth B Ain, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesDavid S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
JCO Oncology Practice|December 19, 2025
Increasing Access and Quality Care for Immune Checkpoint Inhibitor-Related Thyroid DysfunctionAnne K Brinkman, Amori Y Salami-Henry, Lori A Aaron-Brija, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerMartin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
Head & Neck|February 14, 2019
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profilingSaad A Khan, Bo Ci, Yang Xie, et al.
Thyroid : Official Journal of the American Thyroid Association|October 29, 2009
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, David S Cooper, Gerard M Doherty, et al.
Thyroid : Official Journal of the American Thyroid Association|January 4, 2007
Outcomes of patients with differentiated thyroid carcinoma following initial therapyJacqueline Jonklaas, Nicholas J Sarlis, Danielle Litofsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawalHeribert Hänscheid, Michael Lassmann, Markus Luster, et al.
Thyroid : Official Journal of the American Thyroid Association|June 5, 2013
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosisDonald S A McLeod, David S Cooper, Paul W Ladenson, et al.
Thyroid : Official Journal of the American Thyroid Association|September 24, 2009
Recurrence after treatment of micropapillary thyroid cancerDouglas S Ross, Danielle Litofsky, Kenneth B Ain, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesDavid S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Pageof 16